Cigna specialty drug prior authorization — care coordinator playbook

End-to-end PA workflow

Cigna specialty drug prior authorization is a four-phase workflow for the PCC: benefits investigation through CignaforHCP.com (or Availity Essentials, which Cigna participates in), channel determination using the Cigna Specialty Drug List and Express Scripts National Preferred Formulary, PA submission through the correct portal (medical-benefit Cigna direct vs pharmacy-benefit Express Scripts vs Accredo white-bag referral), and reauth tracking. Where billers most often trip is the Express Scripts vs Accredo distinction (they are siblings under Evernorth but operate independently), the Quallent-mandated adalimumab biosimilar step-through, the home-infusion site-of-care steerage on stable patients, and out-of-network denials on non-Accredo specialty pharmacy fulfillment.

Where the Cigna workflow breaks

Four failure patterns drive the bulk of stalled Cigna specialty PAs:

1. Wrong channel (medical vs pharmacy). A pharmacy-benefit drug submitted to CignaforHCP.com precertification (or a medical-benefit drug submitted to Express Scripts) gets bounced silently or routed into a queue with a different criteria set, costing days. The Cigna Specialty Drug List and Express Scripts National Preferred Formulary together determine the correct channel.
2. Missing Quallent biosimilar step-through. Cigna's 2024-2026 biosimilar policy mandates the Quallent-distributed adalimumab biosimilar before alternative anti-TNFs or higher-line biologics (Stelara, Skyrizi, Tremfya) for most autoimmune indications. Submissions without documented Quallent step-through (or a documented exception) draw step-therapy denials.
3. Non-Accredo dispensing for a mandate-list drug. Cigna's specialty pharmacy network heavily favors Accredo. Out-of-network specialty pharmacy denials are among the most common Cigna specialty claim denials. Drugs on the Accredo-mandate portion of the Cigna Specialty Pharmacy Drug List must dispense through Accredo (or a designated REMS pharmacy) regardless of patient or prescriber preference.
4. Home-infusion site-of-care steerage. For clinically stable patients on IVIG, infliximab, vedolizumab, ocrelizumab, and selected enzyme replacement therapies, Cigna often steers to home infusion. HOPD administration requires documented medical necessity (prior infusion reaction, clinical instability, complex comorbidity, monitoring requirement).

Provider portals

Cigna’s specialty drug ecosystem spans at least five distinct provider-facing portals across the Cigna, Evernorth, Express Scripts, and Accredo footprints. The choice of portal is determined by the benefit channel and the dispensing model. Submitting to the wrong portal is the most common operational failure on Cigna PAs.

PA fax numbers by drug class

The most reliable workflow is to download the drug-specific PA form fresh from CignaforHCP.com (or Express Scripts) each time, since the form itself prints the current submission fax at the top. For Quallent-mandated biosimilar step-through documentation, use the Quallent-specific exception form referenced in the current Cigna biosimilar bulletin.

Peer-to-peer (P2P) review requests

Peer-to-peer review is Cigna’s pre-appeal pathway for the prescribing physician to discuss a denied or pended PA with the reviewing medical director. P2P is usually faster than a written Level 1 appeal and can resolve denials based on missing or misinterpreted clinical context. Cigna’s P2P queues are split between Cigna direct (for medical-benefit denials) and Express Scripts (for pharmacy-benefit denials) — verify the queue on the denial letter before calling.

P2P request workflow

1. Read the denial letter carefully. The denial letter lists the P2P scheduling phone number, the queue (Cigna medical-benefit vs Express Scripts pharmacy-benefit vs Cigna Healthcare for Seniors), and the window in which a P2P can be requested (commonly 5-10 business days from the denial date for pre-service denials). Each queue has separate scheduling.
2. Call the P2P scheduling line. Have the member ID, denial reference number, prescribing physician name and direct callback number, and physician’s available windows over the next 3 business days. Cigna typically schedules a 15-minute call window (often 24-72 hours out).
3. Confirm in writing. Document the scheduled time, the queue (commercial / MA / pharmacy / medical), the reviewer specialty if disclosed, and the reference number.
4. Prep the prescriber. Hand off the documentation packet (below) at least 4 hours before the call so the prescriber walks in cold-prepared, not improvising.
5. Document the call. Capture who from Cigna or Express Scripts participated (name and credential), the decision (approve, uphold, downgrade), reference number, and any commitments around resubmission with additional information.

Pre-call documentation checklist

• The original PA submission package (CoverMyMeds export or PDF).
• The denial letter with the stated denial reason and the cited Cigna medical or Express Scripts pharmacy policy reference.
• The most recent clinical note (within the last 30-60 days) supporting the indication.
• Prior therapy list with dates, doses, duration, and documented response or intolerance — including any Quallent-distributed adalimumab biosimilar trial for autoimmune indications.
• Compendia citation supporting any off-label use (NCCN Category 1 or 2A, DrugDex Cat I or IIa, AHFS).
• Laboratory or imaging evidence supporting the indication (e.g., HER2 IHC/FISH for HER2-targeted therapy, EGFR mutation for EGFR-targeted therapy, ACR criteria for RA).
• If site-of-care is the issue: the Cigna site-of-care exception form and the clinical rationale for HOPD administration over home infusion.

Suggested prescriber talking points

Site-of-care policy

Cigna’s site-of-care policy is moderate — less aggressive than UHC’s Outpatient Hospital Site of Care Review program but with a distinctive lean toward home infusion for clinically stable patients. Cigna’s site-of-care medical policy targets a defined list of specialty drugs that can be administered safely outside the HOPD and treats HOPD administration as the higher-cost option requiring documented medical necessity. The drug PA and the site-of-care PA are typically combined on a single submission, but the site-of-care determination is a separate review element and can pend or deny independently.

Site-of-care exception workflow

When HOPD administration is medically necessary, the exception pathway uses the Cigna site-of-care exception form (or the current equivalent listed in the site-of-care medical policy bulletin). The form documents: the clinical reason HOPD or office-based infusion is necessary over home infusion (prior Grade 3+ infusion reaction with intervention, hemodynamic instability, concurrent comorbidity requiring HOPD-level monitoring, complex pediatric or geriatric situation, home-environment factor), the failed or contraindicated alternative sites, the prescribing physician’s attestation, and the planned administration protocol. Submit through CignaforHCP.com Precertification with the drug PA. Site-of-care exceptions are typically decided within the same TAT as the drug PA.

Biosimilar mandate policy

Cigna’s biosimilar mandate is moderate overall but particularly aggressive on adalimumab via the Quallent Pharmaceuticals private-label arrangement. Quallent is Cigna and Express Scripts’ in-house biosimilar arm (parallel to UHC’s Cordavis and Aetna’s CVS-Cordavis) and distributes select adalimumab biosimilars on an exclusive or preferred basis for Cigna and Express Scripts steerage. Outside adalimumab and infliximab, Cigna’s biosimilar policy is less aggressive than UHC’s — biosimilars are preferred but the step-through documentation requirements and the willingness to permit reference-product continuation on stable patients are somewhat looser.

Quallent-specific exception criteria

The Quallent-mandated adalimumab biosimilar step-through is the single most distinctive element of Cigna’s biosimilar policy in 2026. Exception criteria include: documented prior trial of the Quallent-distributed biosimilar with documented intolerance or AE; documented anti-drug antibody formation; loss of clinical response after switch from reference Humira to the Quallent biosimilar; specific clinical scenarios where the Quallent formulation is contraindicated (e.g., citrate-containing formulation in a patient with documented injection-site reactions to citrate-containing adalimumab). Exception submissions should include the prior therapy timeline, the AE or immunogenicity documentation, and the prescribing physician’s clinical rationale, attached to the Quallent-specific exception pathway documented in the current Cigna and Express Scripts biosimilar bulletins.

General biosimilar exception criteria

For non-adalimumab biosimilar mandates, Cigna will consider an exception when the prescriber documents one of: a prior trial of the preferred biosimilar with documented intolerance or AE; documented immunogenicity on the biosimilar; loss of clinical response on the biosimilar after switch; or a clinical situation where switching from reference to biosimilar carries documented risk (rare immunogenicity concerns in stable maintenance patients with specific clinical histories). The exception submission should include the prior therapy timeline, AE or immunogenicity documentation, and the prescriber’s clinical rationale.

Specialty pharmacy network

Cigna’s in-network specialty pharmacy ecosystem is anchored by Accredo, the captive specialty pharmacy under the Evernorth umbrella (sibling to Express Scripts). For most pharmacy-benefit specialty drugs, Accredo is the default and frequently the only in-network specialty pharmacy under the member’s plan. A limited set of additional specialty pharmacies remain in-network for specific drug classes or specific manufacturer-mandated dispensing arrangements (e.g., REMS-restricted distribution). Out-of-network specialty pharmacy denials are among the most common Cigna specialty claim denials — the practice should verify Accredo coverage on every new start.

White-bagging vs brown-bagging vs buy-and-bill

White-bagging (the specialty pharmacy — typically Accredo — dispenses the drug and ships it directly to the site of care, where it is administered) is Cigna’s preferred fulfillment model for designated specialty drugs and is mandatory for drugs on the Cigna Specialty Pharmacy Drug List. The dispensing fee, drug cost, and shipping route through the pharmacy benefit (Express Scripts + Accredo), not through the practice’s buy-and-bill billing.

Brown-bagging (the specialty pharmacy ships the drug to the patient, who brings it to the site of care) is generally not permitted by Cigna for parenteral specialty drugs due to chain-of-custody and stability concerns. Self-administered specialty injectables (subcutaneous biologics) are an exception — the patient may receive the drug at home for self-administration.

Buy-and-bill (the practice purchases the drug through CuraScript SD or another in-network distributor, administers it, and bills the medical benefit for both the drug and the administration) remains the default for most chemotherapy and many oncology biologics administered in HOPD or community oncology settings, and for specialty drugs not on the white-bag mandate. Verify the current sourcing requirement for each drug before ordering inventory — a buy-and-bill claim for a drug on the Accredo-mandate list will be denied for out-of-network specialty pharmacy.

Step therapy requirements

Cigna enforces step therapy across the major specialty therapeutic areas, with the Quallent-mandated adalimumab biosimilar step-through being the most distinctive element of the 2026 policy. The most-mandated step-throughs:

Step therapy exception language

Cigna will consider a step therapy exception when the prescriber documents one of: intolerance (with specific AE description and date), contraindication (with ICD-10 code or clinical reason), failure (with specific clinical metric and treatment duration), or prior payer step-through grandfathering (the patient previously completed the step-through under a prior payer and continued response on the requested agent). Exception submissions should include the prior therapy timeline with dates, doses, durations, and documented outcome, plus the prescribing physician’s clinical rationale. For Quallent-mandated adalimumab biosimilar step-through, use the Quallent-specific exception pathway documented in the current Cigna biosimilar bulletin.

Common denials and how to fix them

Appeals process — 3 levels

Cigna’s appeals structure has three levels for commercial pre-service appeals: Level 1 internal appeal (filed in writing within the timeframe stated in the denial letter, typically 180 days for commercial; TAT 30 calendar days for pre-service standard and 72 hours for expedited); Level 2 internal appeal (where available under the plan configuration — many Cigna plans now go directly from Level 1 to external review; TAT 30 days pre-service); and external review by an Independent Review Entity (IRE) or state-administered external review (filed if internal appeals uphold; TAT typically 45 days standard, 72 hours expedited). For Cigna Healthcare for Seniors (Medicare Advantage), the structure follows CMS rules: Plan Reconsideration → Independent Review Entity (Maximus or C2C) → ALJ → Medicare Appeals Council → Federal Court, with CMS-mandated TATs at each level. Always read the denial letter carefully for the deadline to file each level — missing the window forfeits the appeal right. Note that Cigna’s appeals pathways may be split between Cigna direct (for medical-benefit denials) and Express Scripts (for pharmacy-benefit denials); confirm the queue on the denial letter.

Reauthorization intervals

Reauth workflow

Calendar the reauth date 45-60 days before expiration. Refresh the clinical packet with: the most recent clinical note (within 30-60 days), current labs or imaging required by the drug class, current dose record showing on-label compliance, and any new diagnosis information. For autoimmune biologics, confirm continued response on the Quallent-distributed adalimumab biosimilar where that was the original first-line, or document the exception status if the patient was approved on an alternative. Submit the reauth through the same portal used for the original PA (CignaforHCP.com for medical-benefit, Express Scripts for pharmacy-benefit). If the reauth packet is submitted late and approval lapses, document any therapy continuation gap and prepare a justification for therapy continuation pending re-approval. Cigna’s grace policy for in-progress reauth varies by line of business and is not guaranteed.

Frequently asked questions

Which Cigna portal do I use to submit a specialty drug prior authorization?

Cigna’s specialty drug PA is split across three primary entry points. For medical-benefit drugs (buy-and-bill at the HOPD, infusion center, or office), submit via the Cigna for Health Care Professionals portal at CignaforHCP.com under Precertification. For pharmacy-benefit specialty drugs routed through Express Scripts, submit via the Express Scripts provider portal or CoverMyMeds. For drugs dispensed by Accredo (the captive specialty pharmacy under Evernorth), initiate referral through the Accredo provider portal. Picking the wrong channel is the single most common cause of stalled Cigna specialty PAs.

What is the relationship between Cigna, Evernorth, Express Scripts, and Accredo?

Cigna is now formally The Cigna Group, an umbrella parent that operates two segments: Cigna Healthcare (the insurance arm with commercial, Marketplace, and Medicare Advantage plans) and Evernorth Health Services (the health-services arm). Evernorth houses Express Scripts (the pharmacy benefit manager) and Accredo (the specialty pharmacy), among other subsidiaries. So when a Cigna member’s specialty drug PA routes through Express Scripts for criteria review and is dispensed by Accredo, the PA stays inside one corporate family — but Express Scripts and Accredo operate as separate entities with separate portals, separate workflows, and separate provider reps.

Does Cigna require Quallent biosimilars for adalimumab and other reference biologics?

Quallent Pharmaceuticals is Cigna and Express Scripts’ private-label biosimilar arm — parallel to the UHC relationship with Cordavis and the Aetna relationship with CVS-Cordavis. Quallent distributes select adalimumab biosimilars on an exclusive or preferred basis for Cigna and Express Scripts steerage, and the policy expanded in 2024-2025 to mandate the Quallent-distributed adalimumab biosimilar in most commercial plans before alternative anti-TNFs or higher-line biologics. Quallent’s footprint is narrower than Cordavis’s: Cigna’s biosimilar mandate is most aggressive on adalimumab and infliximab and somewhat less aggressive than UHC on bevacizumab, rituximab, and trastuzumab — but the direction of travel is the same.

What is the difference between submitting a Cigna PA to Express Scripts vs Cigna direct?

It depends on benefit channel and drug type. Self-administered specialty drugs under the pharmacy benefit (most autoimmune biologics, MS oral DMTs, oral oncology agents) flow through Express Scripts for PA criteria review and through Accredo for dispensing. Provider-administered specialty drugs under the medical benefit (chemotherapy biologics, IV anti-VEGF, infusion biologics) typically flow through Cigna direct precertification on CignaforHCP.com. Some drugs straddle both channels — for example, IV infliximab is medical-benefit / Cigna direct, while subcutaneous infliximab (Remsima SC, infliximab biosimilars in SC formulation) may route to Express Scripts under the pharmacy benefit. The Cigna Specialty Drug List is the authoritative source for channel routing.

How aggressive is Cigna site-of-care steerage in 2026?

Cigna’s site-of-care policy is moderate — less aggressive than UHC’s Outpatient Hospital Site of Care Review program but more aggressive than Aetna or Humana on home infusion specifically. Cigna’s most distinctive site-of-care posture is a documented preference for home infusion when patients are clinically stable for that setting. Drugs commonly routed to home infusion include IVIG (and SCIG), infliximab, vedolizumab, ocrelizumab for established patients, and selected enzyme replacement therapies. HOPD administration generally requires documented medical necessity (prior infusion reaction, clinical instability, complex comorbidity, monitoring requirement not available outside HOPD).

Can Cigna members fill specialty drugs at any specialty pharmacy, or do they have to use Accredo?

Cigna’s specialty pharmacy network heavily favors Accredo — the captive Evernorth specialty pharmacy. For most pharmacy-benefit specialty drugs, Accredo is the default in-network specialty pharmacy and frequently the only fully in-network option for a given drug. Out-of-network specialty pharmacy denials are one of the most common Cigna specialty claim denials. A limited set of additional specialty pharmacies remain in-network for specific REMS-restricted drugs or specific manufacturer-mandated distribution arrangements. The Cigna Specialty Pharmacy Drug List should be cross-referenced before a non-Accredo dispenser is used.

What is the Cigna appeals process for a denied specialty drug PA?

Cigna’s appeals structure has three levels for commercial pre-service appeals. Level 1 is a written internal appeal filed within the timeframe stated in the denial letter (typically 180 days for commercial); Cigna’s internal review TAT is typically 30 calendar days for pre-service standard and 72 hours for expedited. Level 2 is a second-level internal appeal available in some plan configurations — many Cigna plans now go directly from Level 1 to external review. Level 3 is external review by an Independent Review Entity (IRE) or, for some plans, a state-administered external review process. For Cigna Medicare Advantage and Part D, the structure follows CMS rules: Plan Reconsideration → IRE (typically Maximus) → ALJ → Medicare Appeals Council → Federal Court.

How do Cigna Healthcare for Seniors (Medicare Advantage) PA criteria differ from commercial Cigna?

Cigna Healthcare for Seniors is the rebranded Medicare Advantage book (formerly Cigna-HealthSpring) and follows CMS Part B and Part D coverage rules layered on top of Cigna’s medical necessity criteria. PA criteria sets differ meaningfully from commercial: Part B drugs follow CMS Local Coverage Determinations (LCDs) and National Coverage Determinations (NCDs) where applicable; Part D follows the CMS-approved formulary with non-formulary exception pathways. Step therapy is permitted in MA Part B as of 2019 and is in active use across many Cigna MA plans. Always confirm the criteria set against the member’s specific plan ID before submission — the same drug can have very different criteria across Cigna commercial, Cigna Marketplace, and Cigna Healthcare for Seniors.

What is Cigna’s typical specialty PA turnaround time?

Standard PA review TAT for Cigna commercial is typically 15 calendar days for non-urgent requests and 72 hours for urgent. Cigna Medicare Advantage Part B drug PA follows CMS standards of 14 calendar days standard and 72 hours expedited; Part D PA follows 72 hours standard and 24 hours expedited. In practice, Express Scripts pharmacy-benefit specialty PAs frequently return within 24-72 hours when all required clinical documentation is present at submission. Missing biosimilar step-through documentation, missing prior therapy records, or wrong-channel submission will extend the review and trigger a request-for-information.

Sources

• Cigna for Health Care Professionals Portal — Precertification reference documentation, current calendar year. Accessible at cignaforhcp.com (provider login required for criteria documents). Paraphrased.
• Express Scripts Provider Portal — National Preferred Formulary, Specialty Drug Management List, and Excluded Drug List, current plan year.
• Accredo Provider Portal — specialty pharmacy referral, white-bag dispensing workflows, patient onboarding documentation.
• Cigna Medical Policy Bulletins — site-of-care, biosimilar substitution, specialty drug management, home-infusion preference policies. Published on CignaforHCP.com under Coverage Policies.
• Cigna Pharmacy Coverage Position Statements (Express Scripts-administered) — PA criteria, step therapy mandates, biosimilar exception pathways.
• Quallent Pharmaceuticals public statements on adalimumab biosimilar private-label distribution arrangements with Cigna and Express Scripts, 2024-2025 (cross-reference for the Quallent mandate scope and exception criteria).
• The Cigna Group corporate communications and Evernorth Health Services public materials on the relationship between Cigna Healthcare, Evernorth, Express Scripts, and Accredo.
• Cigna Healthcare for Seniors (Medicare Advantage, formerly Cigna-HealthSpring) PA criteria and CMS Part B / Part D coverage documents.
• AHIP specialty pharmacy guidance, current edition (cross-reference).
• BCBS Association biosimilar substitution policy framework (used as cross-reference for biosimilar mandate norms across commercial payers).

All sources are publicly available payer policy documents or paraphrased from trade-association educational materials. Payer policy URLs, fax numbers, and criteria change. Verify any operational detail (fax, portal URL, specific PA criteria) on CignaforHCP.com or the Express Scripts provider portal before submission. The methodology by which we resolve source conflicts is described in the Methodology.

Related references